Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 24, 2025 • 5:31 PM ET

Date/Time Source News Release
07/23/2025 07:01 AM EDT Business Wire Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
07/16/2025 07:01 AM EDT Business Wire Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic
06/25/2025 07:01 AM EDT Business Wire Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy
05/15/2025 07:01 AM EDT Business Wire Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
05/14/2025 04:30 PM EDT Business Wire Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
05/08/2025 07:01 AM EDT Business Wire Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
05/07/2025 07:01 AM EDT Business Wire Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
05/01/2025 07:01 AM EDT Business Wire Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
04/29/2025 07:00 AM EDT Business Wire Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04/15/2025 07:01 AM EDT Business Wire Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
Page

Additional News

As of July 24, 2025 • 5:31 PM ET

Date/Time Source News Release
06/25/2025 04:05 PM EDT SeekingAlpha TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
06/25/2025 09:29 AM EDT SeekingAlpha Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%
05/29/2025 12:32 PM EDT Stock Traders Daily (DTIL) Technical Pivots with Risk Controls
05/15/2025 08:15 AM EDT Zacks Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
05/15/2025 07:05 AM EDT SeekingAlpha Precision BioSciences GAAP EPS of -$2.21 misses by $0.49
05/15/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Thursday, May 15th, 2025
05/15/2025 05:30 AM EDT US Earnings Reports Expected earnings - Precision BioSciences Inc.
05/14/2025 06:48 PM EDT KlickAnalytics DTIL - Historical Price Movements Surrounding Earnings
05/14/2025 06:43 PM EDT KlickAnalytics DTIL - Historical Earnings Price Analysis
05/14/2025 06:00 PM EDT SeekingAlpha Here are the major earnings before the open tomorrow
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.